您是第 11121704 位 欢迎访问 中乔新舟官网 ! 全国免费电话:400-038-9959 我的购物车(0) 注 册 / 登 录
扫码关注公众号
您当前的位置:首页 > 产品中心

M-14人黑色素瘤细胞(STR鉴定)

英文名:M-14
货号:ZQ0045
价格:¥1400.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

M-14人黑色素瘤细胞(STR鉴定)

¥1400.00
+

M14人黑色素瘤细胞专用培养基

¥350.00 ¥480.00

配套完培,省时省力,单买细胞无优惠

=

细胞套餐惊爆价

¥1750 ¥1880.00
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

M-14人黑色素瘤细胞

货号

ZQ0045

产品介绍

M-14(也称为M14、UCLA-SO-M14、Melanoma14或M-14)是一种人黑色素瘤细胞系,最初是从一位33岁男性患者的无色素性黑色素瘤中分离建立的。这种细胞系在黑色素瘤的研究中具有重要价值,尤其是在药物筛选和肿瘤生物学特性研究方面。是黑色素瘤研究领域中的一个重要工具,它为科学家们提供了一个模拟人类黑色素瘤在体外条件下行为的模型。

种属

性别/年龄

男/33岁

组织

转移性;右臀,皮下组织

疾病

黑素瘤

细胞类型

肿瘤细胞

形态学

淋巴母细胞样

生长方式

半贴半悬

倍增时间

 ~26.3小时

培养基和添加剂

DMEM(高糖)基础培养基(中乔新舟  货号:ZQ-100)+10%FBS(品牌:中乔新舟 货号:ZQ500-A)+1%PS(中乔新舟  货号:CSP006

推荐完全培养基货号

ZM0045

生物安全等级

BSL - 1

STR位点信息

Amelogenin:X;
CSF1PO:11;
D1S1656:11,12;
D2S441:11,14;
D2S1338:19,24;
D3S1358 :14,16;
D5S818:11,12;
D7S820:8,10;
D8S1179 :13;
D10S1248:14;
D12S391:18,19;
D13S317:12;
D16S539:9,13;
D18S51:13,17;
D19S433:14,15;
D21S11:30;
D22S1045:15;
FGA :21;
SE33:15,22;
TH01:6,7;
TPOX:8,11;
vWA:16,18;

培养条件

95%空气,5%二氧化碳;37℃

抗原表达/受体表达

***  

基因表达

***  

保藏机构

CLS;302163 

供应限制

仅供科研使用

货号

ZQ0045

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用


1、PubMed=56444; DOI=10.1093/jnci/56.1.167
Golub S.H., Hanson D.C., Sulit H.L., Morton D.L., Pellegrino M.A., Ferrone S.
Comparison of histocompatibility antigens on cultured human tumor cells and fibroblasts by quantitative antibody absorption and sensitivity to cell-mediated cytotoxicity.
J. Natl. Cancer Inst. 56:167-170(1976)


2、PubMed=954005
Zielske J.V., Golub S.H.
Fetal calf serum-induced blastogenic and cytotoxic responses of human lymphocytes.
Cancer Res. 36:3842-3846(1976)


3、PubMed=945229; DOI=10.1002/ijc.2910170408
Sulit H.L., Golub S.H., Irie R.F., Gupta R.K., Grooms G.A., Morton D.L.
Human tumor cells grown in fetal calf serum and human serum: influences on the tests for lymphocyte cytotoxicity, serum blocking and serum arming effects.
Int. J. Cancer 17:461-468(1976)


4、PubMed=1260767
Chee D.O., Boddie A.W. Jr., Roth J.A., Holmes E.C., Morton D.L.
Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium.
Cancer Res. 36:1503-1509(1976)


5、PubMed=204583; DOI=10.1002/ijc.2910210308
Saxton R.E., Irie R.F., Ferrone S., Pellegrino M.A., Morton D.L.
Establishment of paired tumor cells and autologous virus-transformed cell lines to define humoral immune responses in melanoma and sarcoma patients.
Int. J. Cancer 21:299-306(1978)


6、PubMed=6876798; DOI=10.1002/jso.2930230404
Chee D.O., Gupta R.K., Morton D.L.
Humoral response of melanoma patients to two different tumor-associated antigens.
J. Surg. Oncol. 23:228-235(1983)


7、PubMed=6470027; DOI=10.1007/BF00402467
Katano M., Saxton R.E., Cochran A.J., Irie R.F.
Establishment of an ascitic human melanoma cell line that metastasizes to lung and liver in nude mice.
J. Cancer Res. Clin. Oncol. 108:197-203(1984)


8、PubMed=6500744; DOI=10.1002/ijc.2910340511
Ferrini U., Falcioni R., Delpino A., Cavaliere R., Zupi G., Natali P.G.
Heat-shock proteins produced by two human melanoma cell lines: absence of correlation with thermosensitivity.
Int. J. Cancer 34:651-655(1984)


9、PubMed=3658923; DOI=10.1016/0143-4004(87)90053-1
Takahashi H., Adachi S., Yoshiya N., Suzuki T., Kanazawa K., Takeuchi S.
Expression of HLA-DR molecules in human gestational choriocarcinoma cell lines and malignant cell lines.
Placenta 8:293-298(1987)


10、PubMed=3674770
Greco C., Zupi G.
Biological features and in vitro chemosensitivity of a new model of human melanoma.
Anticancer Res. 7:839-844(1987)


11、PubMed=3046746; DOI=10.1007/BF00200019
Wong J.H., Aguero B., Gupta R.K., Morton D.L.
Recovery of a cell surface fetal antigen from circulating immune complexes of melanoma patients.
Cancer Immunol. Immunother. 27:142-146(1988)


12、PubMed=1918136; DOI=10.1083/jcb.115.1.191
Quax P.H.A., van Muijen G.N.P., Weening-Verhoeff E.J.D., Lund L.R., Dano K., Ruiter D.J., Verheijen J.H.
Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
J. Cell Biol. 115:191-199(1991)


13、PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)


14、PubMed=2060184; DOI=10.1007/BF01753729
van Muijen G.N.P., Cornelissen I.L.M.H.A., Jansen K.F.J., Figdor C.G., Johnson J.P., Brocker E.-B., Ruiter D.J.
Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice.
Clin. Exp. Metastasis 9:259-272(1991)


15、PubMed=8618233; DOI=10.1093/jnci/88.7.419
Leonetti C., D'Agnano I., Lozupone F., Valentini A., Geiser T., Zon G., Calabretta B., Citro G., Zupi G.
Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
J. Natl. Cancer Inst. 88:419-429(1996)


16、PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)


17、PubMed=11121133; DOI=10.1046/j.1523-1747.2000.00199.x
Lacal P.M., Failla C.M., Pagani E., Odorisio T., Schietroma C., Falcinelli S., Zambruno G., D'Atri S.
Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor.
J. Invest. Dermatol. 115:1000-1007(2000)


18、PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)


19、PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11.1-11.8(2005)


20、PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)


21、PubMed=18277095; DOI=10.4161/cbt.7.5.5712
Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T.
Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.
Cancer Biol. Ther. 7:699-708(2008)


22、PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)


23、PubMed=19549886; DOI=10.1158/0008-5472.CAN-09-1528
Chambers A.F.
MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?
Cancer Res. 69:5292-5293(2009)


24、PubMed=19727395; DOI=10.1371/journal.pone.0006888
Wadlow R.C., Wittner B.S., Finley S.A., Bergquist H., Upadhyay R., Finn S.P., Loda M., Mahmood U., Ramaswamy S.
Systems-level modeling of cancer-fibroblast interaction.
PLoS ONE 4:E6888-E6888(2009)


25、PubMed=19799798; DOI=10.1186/1471-2407-9-352
Casula M., Muggiano A., Cossu A., Budroni M., Caraco C., Ascierto P.A., Pagani E., Stanganelli I., Canzanella S., Sini M.C., Palomba G., Palmieri G.
Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy.
BMC Cancer 9:352.1-352.11(2009)


26、DOI=10.4172/2157-7145.S2-005
Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M., Hart R.P., Furtado M.R.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
J. Forensic Res. 2 Suppl. 2:5-5(2011)


27、PubMed=21863025; DOI=10.1038/bjc.2011.324
De Luca A., Lamura L., Strizzi L., Roma C., D'Antonio A., Margaryan N.V., Pirozzi G., Hsu M.-Y., Botti G., Mari E., Hendrix M.J.C., Salomon D.S., Normanno N.
Expression and functional role of CRIPTO-1 in cutaneous melanoma.
Br. J. Cancer 105:1030-1038(2011)


28、PubMed=22068913; DOI=10.1073/pnas.1111840108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)


29、PubMed=22347499; DOI=10.1371/journal.pone.0031628
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
PLoS ONE 7:E31628-E31628(2012)


30、PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)


31、PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)


32、PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)


33、PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)


34、PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20.1-20.13(2013)


35、PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)


36、PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)


37、PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)


38、PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20.1-20.11(2016)


39、PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)


40、PubMed=28940260; DOI=10.1002/ijc.31067
Korch C.T., Hall E.M., Dirks W.G., Ewing M., Faries M., Varella-Garcia M., Robinson S., Storts D.R., Turner J.A., Wang Y., Burnett E.C., Healy L.E., Kniss D.A., Neve R.M., Nims R.W., Reid Y.A., Robinson W.A., Capes-Davis A.
Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line.
Int. J. Cancer 142:561-572(2017)


41、PubMed=29492214; DOI=10.18632/oncotarget.23989
Sini M.C., Doneddu V., Paliogiannis P., Casula M., Colombino M., Manca A., Botti G., Ascierto P.A., Lissia A., Cossu A., Palmieri G.
Genetic alterations in main candidate genes during melanoma progression.
Oncotarget 9:8531-8541(2018)


42、PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)


43、PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
      上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经十多年发展,...
联系我们 / Contact
电 话:021-56760357;021-56760351
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved. 网站地图

沪公网安备 31011002001038号

技术支持:攸攸网络 沪ICP备14008091号